奥拉西坦治疗脑出血后认知障碍的效果及安全性的meta分析

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (1384 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the efficacy and safety of Oxiracetam in the treatment of cognitive impairment after intracerebral hemorrhage. Methods Randomized controlled trials of Oxiracetam for cognitive impairment after intracerebral hemorrhage were searched in CNKI, Wanfang Data, VIP, CBM, EMbase, PubMed, and the Cochrane Library. The retrieval period is from inception to November 2020. Meta-analysis was performed using RevMan 5.3 software. Results A total of 616 patients were included in eight literatures, 310 in experimental group and 306 in control group. The mini mental status examination (MMSE) score (MD = 8.85, 95%CI: 4.82-12.87, P ＜ 0.0001) and Barthel index (MD = 17.21, 95%CI: 15.29-19.14, P ＜ 0.0001) in experimental group were higher than those in control group. Further subgroup analysis showed that the MMSE score (MD = 12.33, 95%CI: 8.54-16.11, P ＜ 0.000 01) and Barthel index (MD = 20.44, 95%CI: 17.77-23.11, P ＜ 0.000 01) of static drops group, the MMSE score (MD = 4.19, 95%CI: 2.20-6.18, P ＜ 0.0001), and Barthel index (MD = 13.73, 95%CI: 10.95-16.50, P ＜ 0.000 01) of oral group were higher than those in control group. Hasegawa dementia scale score in the experimental group was higher than that in the control group (MD = 3.84, 95%CI: 1.65-6.03, P = 0.0006), and National Institutes of Health stroke scale score was lower than that in the control group (MD = -4.31, 95%CI: -6.37 to -2.25, P ＜ 0.0001). There was no significant difference in the incidence of adverse reactions between the two groups (RR = 1.18, 95%CI: 0.62-2.22, P = 0.62). Conclusion Oxiracetam has significant effect in improving cognitive function, activities of daily living and neurological deficit symptoms of patients with intracerebral hemorrhage.

Key words： Oxiracetam Intracerebral hemorrhage Cognitive impairment Meta-analysis Randomized controlled trial

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XUE Daojin1 YIN Lianjun1
	2 MENG Jinyuan1
	2 ZHEN Zheng1
	2 ZHAN Jie1 SHEN Youbi1 PENG Zizhuang1 HUANG Tao1
	2

Cite this article:

XUE Daojin1 YIN Lianjun1,2 MENG Jinyuan1,2 ZHEN Zheng1, et al. Meta-analysis of the efficacy and safety of Oxiracetam in the treatment of cognitive impairment after intracerebral hemorrhage#br#[J]. 中国医药导报, 2021, 18(29): 77-81.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I29/77

[1] Krishnamurthi RV，Ikeda T，Feigin VL. Global，regional and country-specific burden of ischaemic stroke，intracerebral haemorrhage and subarachnoid haemorrhage：a systematic analysis of the global burden of disease study 2017 [J]. Neuroepidemiology，2020，54（2）：171-179.
[2] Godoy DA，Nú?觡ez-Pati?觡o RA，Zorrilla-Vaca A，et al. Intracranial hypertension after spontaneous intracerebral hemorrhage：a systematic review and meta-analysis of prevalence and mortality rate [J]. Neurocrit Care，2019，31（1）：176-187.
[3] Donnellan C，Werring D. Cognitive impairment before and after intracerebral haemorrhage：a systematic review [J]. J Neurol Sci，2020，41（3）：509-527.
[4] Planton M，Saint-Aubert L，Raposo N，et al. High prevalence of cognitive impairment after intracerebral hemorrhage [J]. PLoS One，2017，12（6）：e0178886.
[5] Liao X，Zuo L，Zhang N，et al. The occurrence and longitudinal changes of cognitive impairment after acute ischemic stroke [J]. Neuropsychiatr Dis Treat，2020，16：807.
[6] Li XX，Liu SH，Zhuang SJ，et al. Effects of oxiracetam combined with ginkgo biloba extract in the treatment of acute intracerebral hemorrhage：A clinical study [J]. Genes Brain Behav，2020，10（8）：e01661.
[7] Woodruff-Pak DS. Preclinical experiments on cognition enhancement in Alzheimer’s Disease：Drugs affecting nicotinic acetylcholine receptors [J]. Drug Dev Res，2002，56（3）：335-346.
[8] Wang B，Zhong L，Qiao P，et al. Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment [J]. Pak J Pharm Sci，2020，33：417-422.
[9] Xu J，Qi Q，Lv P，et al. Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway [J]. Braz J Med Biol Res，2019，52（11）：e8371.
[10] Higgins J，Green SE. Cochrane handbook for systematic reviews of interventions version 5.1.0. the cochrane collaboration（Eds）[J]. N Schmied Arch Pharmacol，2011，5（2）：S38.
[11] 苏永峰.奥拉西坦对高血压脑出血患者认知和生活自理能力的影响效果观察[J].中国医药科学，2013，3（9）：93-94.
[12] 田学文，童秀甜，董曼丽，等.奥拉西坦对高血压脑出血术后恢复期患者日常生活活动和认知功能的影响[J].中国临床康复，2005，9（13）：24-26.
[13] 尹浩，游潮，李国平，等.奥拉西坦改善高血压脑出血患者认知功能的对照研究[J].四川医学，2008，29（4）：392-394.
[14] 孙小兰，尹浩，丁昊，等.奥拉西坦改善高血压脑出血患者认知功能的临床研究[J].中国医药导报，2007，4（30）：38-39.
[15] 沈福玉，黎宏斐，单云霞.奥拉西坦和毗拉西坦治疗高血压脑出血的疗效对比[J].实用心脑肺血管病杂志，2014，22（5）：81-82.
[16] 海丽萍.奥拉西坦用于高血压脑出血的效果观察[J].中国现代药物应用，2013，7（19）：159-160.
[17] 华金宝.奥拉西坦用于高血压脑出血患者大脑认知功能恢复的临床观察[J].中国医院药学杂志，2008，28（14）：1200-1202.
[18] 孙炜，李瑾.奥拉西坦治疗老年脑出血后认知功能障碍的疗效及不良反应[J].中国实用神经疾病杂志，2016， 19（19）：64-66.
[19] McGurgan IJ，Ziai WC，Werring DJ，et al. Acute intra-cerebral haemorrhage：diagnosis and management [J]. Pract Neurol，2021，21（2）：128-136.
[20] Moulin S，Cordonnier C. Role of cerebral microbleeds for intracerebral haemorrhage and dementia [J]. Curr Neurol Neurosci Rep，2019，19（8）：1-8.
[21] Xiong L，Reijmer YD，Charidimou A，et al. Intracerebral hemorrhage and cognitive impairment [J]. Biochim Biophys Acta，2016，1862（5）：939-944.
[22] 刘若茜，陶带花，韦艳秋，等.脑出血认知功能障碍研究进展[J].中国卒中杂志，2019，14（2）：127-131.
[23] 容玉仪，麦蕾蕾，谭柏森.乌司他丁联合奥拉西坦治疗脑出血患者疗效及对血清中MMP-9、TIMP-1水平影响观察[J].中国医药科学，2020，10（12）：63-66.
[24] Zhang H，Jia L，Jia J. Oxiracetam Offers Neuroprotection by Reducing Amyloid β-Induced Microglial Activation and Inflammation in Alzheimer’s Disease [J]. Front Neurol，2020，11：623.
[25] 黎希年，洪荣庆，曾纪超，等.丁苯酞联合奥拉西坦治疗急性脑梗死伴认知功能障碍的效果分析[J].中国医药科学，2019，9（3）：66-68.
[26] 赵宗刚，金辉，王胜男.奥拉西坦对大鼠脑梗死的脑保护作用及机制[J].中国动脉硬化杂志，2019，27（11）：944-949.
[27] 程海冰.依达拉奉与奥拉西坦联合治疗急性脑梗死的临床研究[J].中国现代医生，2019，57（5）：45-47.
[28] 相建峰，陈亮，王征，等.奥拉西坦通过Wnt/β-catenin减轻大鼠脑缺血再灌注损伤的实验研究[J].疑难病杂志，2019，18（10）：1051-1055，1081.
[29] 陈卫平，林莉，徐阳.奥拉西坦联合脑苷肌肽治疗新生儿缺氧缺血性脑病的临床效果[J].中国当代医药，2019， 26（32）：98-100.
[30] Sun Y，Xu B，Zhang Q. Nerve growth factor in combination with Oxiracetam in the treatment of Hypertensive Cerebral Hemorrhage [J]. Pak J Med Sci Q，2018，34（1）：73-77.
[31] 王丹.奥拉西坦在新生小鼠缺氧缺血性脑损伤中的作用及机制研究[D].济南：山东大学，2020.
[32] Liu H，Jiang H，Wang C，et al. （S）-Oxiracetam is the active ingredient in oxiracetam that alleviates the cognitive impairment induced by chronic cerebral hypoperfusion in rats [J]. Sci Rep，2017，7（1）：1-14.